ホーム › 急性骨髄性白血病 › ノースカロライナ › Durham
Durham、NCにおける急性骨髄性白血病の臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する33件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Duke University Medical Center, Durham
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
被験者募集中第1/2相
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
被験者募集中第1相
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
被験者募集中第1/2相
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10マイル先
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
被験者募集中第3相
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · 10マイル先
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
被験者募集中第1相
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10マイル先
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
被験者募集中第1相
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
被験者募集中第1/2相
- Research Site, Durham
- Research Site, Chapel Hill · 10マイル先
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
被験者募集中第2相
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
被験者募集中
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Registry of Older Patients With Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
被験者募集中第2相
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Study of Revumenib and Mezigdomide in People With Leukemia
被験者募集中第1/2相
- University of North Carolina (Data Collection Only), Chapel Hill · 10マイル先
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
被験者募集中第1相
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
被験者募集中第2/3相
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10マイル先
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
被験者募集中第1相
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
被験者募集中
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1/2相
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
被験者募集中健康なボランティア歓迎
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
- Washington, DC24件の研究
Durhamにおける他の研究
- 乳がん64件の研究
- がん（全種類）58件の研究
- 非小細胞肺癌39件の研究
- 多発性骨髄腫37件の研究
- 転移性癌33件の研究
- 前立腺がん32件の研究
- 肺がん32件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 慢性リンパ性白血病27件の研究
- 心不全26件の研究
- 膵臓がん24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。